Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer

NCT07401537 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

416

Enrollment

OTHER

Sponsor class

Conditions

Triple -Negative Breast Cancer
Breast Cancer

Interventions

DRUG: Extended-Dose Interval Immunotherapy
DRUG: Standard-Dose Interval Immunotherapy

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University